



Boal, A. H., Gill, J. M.R. and Sattar, N. (2020) Shorter sleep: a new potential target to address cardiovascular and metabolic risk? *Cardiovascular Research*, 116(8), pp. 1407-1409. (doi: [10.1093/cvr/cvz330](https://doi.org/10.1093/cvr/cvz330)).

This is the author's final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/204991/>

Deposited on: 04 December 2019

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

1 **Shorter sleep: a new potential target to address cardiovascular and metabolic risk?**

2 Angela H Boal, Jason MR Gill, Naveed Sattar

3 Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK

4

5 **Corresponding Author**

6 Naveed Sattar, Institute of Cardiovascular and Medical Sciences, University of Glasgow,

7 BHF Glasgow Cardiovascular Research Centre, 126 University Place, Glasgow, G12 8TA, UK

8 Tel: 0141 330 3419

9 Email: Naveed.sattar@glasgow.ac.uk

10

11 Category of manuscript: Invited Editorial

12 Total word count: 1809

13 Manuscript word count: 831

14

1 Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, with coronary
2 heart disease (CHD) accounting for more than 50% of cases. While recent advances in treatment
3 have led to CVD dipping below cancer as the leading cause of death in some high income countries,
4 it is important to note that 80% of CVD deaths now occur in low and middle-income countries.^{1,2}
5 It has long been understood that factors contributing to this large global burden of disease include
6 hypertension, smoking, physical inactivity, obesity and hypercholesterolaemia.^{2,3} However, these
7 variables alone do not fully explain the association. More recently, a wealth of evidence has linked
8 low socioeconomic status (SES) to adverse CV outcomes.⁴ This evidence has led to SES being
9 incorporated into some risk scores for CV disease, including the ASSIGN score ("ASSessing
10 cardiovascular risk using SIGN")⁵ and QRISK3 score,⁶ although interestingly, SES has not yet been
11 fully incorporated into SCORE: the European risk score calculator.⁷ This strong independent link
12 between socioeconomic status and cardiovascular outcomes has fuelled research to try and
13 determine the underlying mechanisms. Potential factors have included SES-driven differences in
14 smoking, alcohol, obesity, healthcare accessibility,⁴ diet and inflammation,^{4,8} and recent data from
15 UK Biobank suggest that socioeconomic deprivation potentiates the adverse association between
16 unhealthy lifestyle factors and (CVD and all-cause) mortality.⁹ However, other unmeasured factors
17 are also likely to be relevant.

18

19 In recent years, sleep has evolved as a potential lifestyle factor which may be relevant to both
20 metabolic and cardiovascular risk. In a meta-analysis of self-reported sleep duration and
21 cardiovascular outcomes in prospective studies, Cappuccio et al, found a 'U-shaped' association
22 between sleep duration and risk of developing CHD with both shorter and longer durations of sleep
23 being associated with a greater risk of developing or dying from CHD and stroke disease.¹⁰ The
24 accumulating evidence was thought sufficiently robust for a recent USA-based CVD prevention
25 guideline recommending targeting short sleep duration and poor sleep quality as another method to
26 help lessen risk.¹¹

1 In this issue of Cardiovascular Research, Petrovic and colleagues report the results of a large
2 observational study on eight European Cohorts with a total of more than 111,000 participants. They
3 investigate the role of sleep duration in explaining socioeconomic status links to cardiovascular
4 disease. Their data suggest that both father's and adult occupational position are associated with
5 abnormal sleep duration patterns, with a stronger association for short sleep than long sleep. In
6 addition, they found an inverse association between both life-course SES indicators and CHD, and
7 that the association between adult occupational position and CHD was partly explained by short
8 sleep duration, at least in men. This study has multiple strengths including its large size and being
9 the first to investigate sleep duration and CV disorders across life socioeconomic status. However,
10 there are some limitations which include recall bias of self-reported sleep duration and lack of
11 adjustment for some potential confounders including hypertension, hyperlipidaemia and
12 environmental factors. Even so, this paper adds key insights into our understanding of the
13 associations between SES, sleep and CVD.

14

15 Nevertheless, how can we determine whether shorter or longer sleep durations are causal risk
16 factors for adverse CVD outcomes? Here we have to turn to genetic studies. Dashti et al identified 78
17 (76 novel) gene loci for sleep duration that implicate multiple biological pathways. They then
18 compared observational and genetic data linking sleep to adverse outcomes.¹² Whilst observational
19 data showed short sleep was associated with a 20% higher multivariate adjusted risk of incident
20 myocardial infarction and long sleep with a 34% higher risk, Mendelian randomisation analyses using
21 the discovered sleep genes was consistent only with a casual effect of shorter sleep duration on
22 myocardial infarction in both CARDIoGRAMplusC4D and UK Biobank¹³ (Figure 1). Thus while the
23 mechanisms underpinning the association between long sleep duration and CVD risk are still unclear
24 – this may reflect reverse causality (i.e. those with pre-existing illness sleeping longer) or poor sleep
25 quality, which in itself may increase CHD risk,¹⁴ thereby necessitating longer sleep duration to feel

1 rested – there is accumulating evidence that short sleep is likely to play a causal role in mediating
2 CVD risk.

3

4 If all of the above is true, can we help short sleepers sleep longer? Recently in a randomised clinical
5 trial of 1711 people, Espie and colleagues reported that the use of digital cognitive behavioural
6 therapy is effective in improving functional health, psychological wellbeing and sleep-related quality
7 of life in people reporting insomnia symptoms.¹⁵ This trial suggested that sleep interventions can
8 improve insomnia symptoms as well as functional health, psychological well-being and sleep-related
9 quality of life. Extending such research, it should be possible to conduct a randomised trial of sleep
10 interventions for the prevention of CV disease or diabetes (Figure 1). Such trials would take time,
11 effort, and careful design, but they are needed if sleep interventions are to have wider impact in
12 preventative medicine. Only by showing sleep interventions improve either proven casual risk
13 factors, or better hard outcomes, will sleep interventions hit prime time in the CV and metabolic
14 arenas.

15

16 **Conflict of Interest**

17 None declared

18

19 **Acknowledgements**

20 Thanks to Liz Coyle (University of Glasgow) for her assistance with formatting and drafting the figure.

21

22

1 **Figure Legend**

2 This figure depicts the observational associations between sleep duration and cardiovascular
3 outcomes. Generally, both short and long sleep are associated with greater CV risks compared to
4 those who sleep between 6 to 9 hours per night. That noted, recent genetic work suggest shorter
5 sleep may be causally linked to such CV outcomes whereas this appears not to be the case for longer
6 sleep durations. As many conditions can lead people to sleep for longer, this association may
7 represent reverse causality or residual confounding. In particular, long sleep may be a consequence
8 of poor sleep quality, which in itself may be associated with CHD risk. The totality of work sets the
9 scene for sleep intervention trials in the cardiovascular arena.

10

11

12

1 References

- 2 1. Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, Diaz R, Avezum A,
3 Oliveira GBF, Wielgosz A, Parambath SR, Mony P, Alhabib KF, Temizhan A, Ismail N, Chifamba
4 J, Yeates K, Khatib R, Rahman O, Zatonska K, Kazmi K, Wei L, Zhu J, Rosengren A, Vijayakumar
5 K, Kaur M, Mohan V, Yusufali A, Kelishadi R, Teo KK, et al. Variations in common diseases,
6 hospital admissions, and deaths in middle-aged adults in 21 countries from five continents
7 (PURE): a prospective cohort study. *Lancet* 2019;
- 8 2. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control.
9 *World Heal Organ* 2011;2–14.
- 10 3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR,
11 Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-
12 Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M,
13 Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, et al. A
14 comparative risk assessment of burden of disease and injury attributable to 67 risk factors
15 and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden
16 of Disease Study 2010. *Lancet* Lancet Publishing Group; 2012;**380**:2224–2260.
- 17 4. Méjean C, Droomers M, Schouw YT Van Der, Sluijs I, Czernichow S, Grobbee DE, Bueno-De-
18 Mesquita HB, Beulens JWJ. The contribution of diet and lifestyle to socioeconomic
19 inequalities in cardiovascular morbidity and mortality. *Int J Cardiol* 2013;**168**:5190–5195.
- 20 5. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to
21 cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended
22 Cohort (SHHEC). *Heart* 2007;**93**:172–176.
- 23 6. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and
24 validation of QRISK, a new cardiovascular disease risk score for the United Kingdom:
25 Prospective open cohort study. *Br Med J* 2007;**335**:136–141.
- 26 7. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, Backer G De, Bacquer D De,

- 1 Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H,
2 Tverdal A, Wedel H, Whincup P, Witheimsen L, Graham IM. Estimation of ten-year risk of fatal
3 cardiovascular disease in Europe: The SCORE project. *Eur Heart J* 2003;**24**:987–1003.
- 4 8. Aiello AE, Kaplan GA. Socioeconomic position and inflammatory and immune biomarkers of
5 cardiovascular disease: applications to the Panel Study of Income Dynamics. *Biodemography*
6 *Soc Biol* 2009;**55**:178–205.
- 7 9. Foster HME, Celis-Morales CA, Nicholl BI, Petermann-Rocha F, Pell JP, Gill JMR, O'Donnell CA,
8 Mair FS. The effect of socioeconomic deprivation on the association between an extended
9 measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of
10 the UK Biobank cohort. *Lancet Public Heal* Elsevier Ltd; 2018;**3**:e576–e585.
- 11 10. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts
12 cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. *Eur*
13 *Heart J* 2011;**32**:1484–1492.
- 14 11. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD,
15 Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS,
16 Williams KA, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of
17 Cardiovascular Disease: Executive Summary: A Report of the American College of
18 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*
19 NLM (Medline); 2019;**140**:e563–e595.
- 20 12. Dashti HS, Jones SE, Wood AR, Lane JM, Hees VT van, Wang H, Rhodes JA, Song Y, Patel K,
21 Anderson SG, Beaumont RN, Bechtold DA, Bowden J, Cade BE, Garaulet M, Kyle SD, Little MA,
22 Loudon AS, Luik AI, Scheer FAJL, Spiegelhalter K, Tyrrell J, Gottlieb DJ, Tiemeier H, Ray DW,
23 Purcell SM, Frayling TM, Redline S, Lawlor DA, Rutter MK, et al. Genome-wide association
24 study identifies genetic loci for self-reported habitual sleep duration supported by
25 accelerometer-derived estimates. *Nat Commun* 2019;**10**:1100.
- 26 13. Daghlas I, Dashti HS, Lane J, Aragam KG, Rutter MK, Saxena R, Vetter C. Sleep Duration and


1 Myocardial Infarction. *J Am Coll Cardiol* Elsevier USA; 2019;**74**:1304–1314.

2 14. Kwok CS, Kontopantelis E, Kuligowski G, Gray M, Muhyaldeen A, Gale CP, Peat GM, Cleator J,
3 Chew-Graham C, Loke YK, Mamas MA. Self-Reported Sleep Duration and Quality and
4 Cardiovascular Disease and Mortality: A Dose-Response Meta-Analysis. *J Am Heart Assoc*
5 2018;**7**:e008552.

6 15. Espie CA, Emsley R, Kyle SD, Gordon C, Drake CL, Siriwardena AN, Cape J, Ong JC, Sheaves B,
7 Foster R, Freeman D, Costa-Font J, Marsden A, Luik AI. Effect of Digital Cognitive Behavioral
8 Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life:
9 A Randomized Clinical Trial. *JAMA psychiatry* 2019;**76**:21–30.

10

1 **Figure 1**



2